Biotechnology firm Adcendo, which focuses on developing novel cancer therapies, has announced the successful closure of an oversubscribed $75 million Series C financing round. This significant capital injection was led by the esteemed life sciences investor Jeito Capital. The proceeds are designated to accelerate the clinical development of the company's pipeline of first-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical needs.
Strategic Allocation of Capital
The newly acquired funds will be strategically allocated to advance Adcendo's three lead clinical candidates through crucial upcoming milestones. A key focus will be the Phase I cohort expansion study for ADCE-T02, a Tissue Factor ADC being tested in multiple tumor indications. The capital will also support the ADCE-D01 dose escalation and expansion study in soft tissue sarcoma and the ADCE-B05 dose escalation study in squamous cell carcinomas.
Investor Confidence and Syndicate
The financing round attracted a distinguished syndicate of new and existing investors, demonstrating strong market confidence in Adcendo's platform. Jeito Capital led the round, with new participation from Vida Ventures, BPI France, and the Export and Investment Fund of Denmark (EIFO). Crucially, the company received continued support from all its existing investors, including TCGX, RA Capital Management, and Novo Holdings, highlighting their sustained belief in the company's vision.
Leadership and Vision
Michael Pehl, Chief Executive Officer of Adcendo, emphasized that this successful fundraising empowers the company to advance its portfolio of breakthrough ADCs. He expressed enthusiasm for the continued clinical momentum of their leading drug candidates, which are designed for underserved patient populations. Pehl confirmed that the backing will directly support the progression of ADCE-T02, ADCE-D01, and ADCE-B05 toward important data readouts.
Ksenija Pavletic, a General Partner at Jeito Capital, commented on Adcendo's standout position within the highly competitive ADC field. She noted the company's impressive combination of bold scientific innovation with a robust and well-executed clinical development strategy. Pavletic added that the seasoned team of drug developers further strengthens their conviction in Adcendo's mission to deliver next-generation therapies to patients.
Strengthening the Board of Directors
As part of the financing agreement, Adcendo will strengthen its governance and strategic leadership by welcoming two new members to its Board of Directors. Ksenija Pavletic of Jeito Capital and Rajul Jain of Vida Ventures will bring their extensive industry experience to the company. These appointments are poised to provide valuable guidance as Adcendo navigates its next phase of clinical development and corporate growth.
This substantial $75 million capital raise represents a pivotal moment for Adcendo, equipping it with the financial runway to pursue critical clinical objectives. The overwhelming support from a global consortium of investors validates the promise of its targeted ADC technology and its potential to redefine cancer care. With this funding, Adcendo is strategically positioned to achieve key milestones and advance its mission of developing transformative treatments for patients.